Cytostatic activity of peripheral blood monocytes against bronchogenic carcinoma cells in patients with lung cancer. 1979

E Yanagawa, and K Yasumoto, and H Manabe, and N Nagano, and N Hirota, and M Ohta, and T Hattori, and K Nomoto, and I Azuma, and Y Yamamura

Cytostatic acitivity of peripheral blood monocytes against cultured cell lines of bronchogenic carcinoma was examined in patients with lung cancer. Cytostatic activity in lung cancer patients with neither augmented nor suppressed as compared with that of controls such as normal healthy persons, patients with malignancies other than lung cancer, and patients with benign respiratory diseases. There was no correlation between the cytostatic activity of monocytes and the advance of clinical stages of the disease. Conventional modalities of anticancer treatments such as surgery, radiotherapy, chemotherapy, and their combination therapy had no effect on cytostatic activity of peripheral blood monocytes. However, adequate immunotherapy with nocardia rubra cell-wall skeleton augmented the cytostatic activity of peripheral blood monocytes, although adequate immunotherapy with Mycobacterium bovis BCG cell-wall skeleton had no effect.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D002283 Carcinoma, Bronchogenic Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA. Carcinoma, Bronchial,Bronchial Carcinoma,Bronchial Carcinomas,Bronchogenic Carcinoma,Bronchogenic Carcinomas,Carcinomas, Bronchial,Carcinomas, Bronchogenic
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D001500 BCG Vaccine An active immunizing agent and a viable avirulent attenuated strain of MYCOBACTERIUM BOVIS, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity. Bacillus Calmette Guerin Vaccine,Calmette Guerin Bacillus Vaccine,Calmette's Vaccine,Calmette Vaccine,Calmettes Vaccine,Vaccine, BCG,Vaccine, Calmette's
D018288 Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7) Carcinoma, Oat Cell,Oat Cell Carcinoma,Small Cell Carcinoma,Carcinomas, Oat Cell,Carcinomas, Small Cell,Oat Cell Carcinomas,Small Cell Carcinomas

Related Publications

E Yanagawa, and K Yasumoto, and H Manabe, and N Nagano, and N Hirota, and M Ohta, and T Hattori, and K Nomoto, and I Azuma, and Y Yamamura
August 1976, Gan,
E Yanagawa, and K Yasumoto, and H Manabe, and N Nagano, and N Hirota, and M Ohta, and T Hattori, and K Nomoto, and I Azuma, and Y Yamamura
January 1982, Cancer immunology, immunotherapy : CII,
E Yanagawa, and K Yasumoto, and H Manabe, and N Nagano, and N Hirota, and M Ohta, and T Hattori, and K Nomoto, and I Azuma, and Y Yamamura
July 1988, Biulleten' eksperimental'noi biologii i meditsiny,
E Yanagawa, and K Yasumoto, and H Manabe, and N Nagano, and N Hirota, and M Ohta, and T Hattori, and K Nomoto, and I Azuma, and Y Yamamura
February 1979, Gan,
E Yanagawa, and K Yasumoto, and H Manabe, and N Nagano, and N Hirota, and M Ohta, and T Hattori, and K Nomoto, and I Azuma, and Y Yamamura
December 1981, Gan,
E Yanagawa, and K Yasumoto, and H Manabe, and N Nagano, and N Hirota, and M Ohta, and T Hattori, and K Nomoto, and I Azuma, and Y Yamamura
September 1993, International journal of cancer,
E Yanagawa, and K Yasumoto, and H Manabe, and N Nagano, and N Hirota, and M Ohta, and T Hattori, and K Nomoto, and I Azuma, and Y Yamamura
January 1982, Cancer immunology, immunotherapy : CII,
E Yanagawa, and K Yasumoto, and H Manabe, and N Nagano, and N Hirota, and M Ohta, and T Hattori, and K Nomoto, and I Azuma, and Y Yamamura
January 1976, Neoplasma,
E Yanagawa, and K Yasumoto, and H Manabe, and N Nagano, and N Hirota, and M Ohta, and T Hattori, and K Nomoto, and I Azuma, and Y Yamamura
August 1983, Gan,
E Yanagawa, and K Yasumoto, and H Manabe, and N Nagano, and N Hirota, and M Ohta, and T Hattori, and K Nomoto, and I Azuma, and Y Yamamura
April 1978, Gan,
Copied contents to your clipboard!